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Abstract
Background: The pelvic inflammatory disease (PID) diagnosis is mostly based on clinical findings.
However, few studies have examined the clinical basis for the diagnostics of PID, which was the aim
of this study.
Methods: A retrospective study was performed of 189 out-patients diagnosed as having PID at
the obstetric and gynecological emergency department of a Swedish university hospital. Data on
symptoms, signs, pelvic examination and laboratory tests were extracted from the electronic
medical records in comparison with the diagnostic criteria of the PID Guideline of the US Center
of Disease Control from 2002 (CDC 2002 Guidelines).
Results: Eight symptoms in varying combinations were associated with the PID diagnosis. Most of
them are mentioned in the CDC 2002 Guidelines. Detected rates of C. Trachomatis (CT) and N.
Gonorrhoeae (NG) were 5% and 0%, respectively, among the tested patients (CT = 52% and NG
= 12%). The C-reactive protein was normal in the majority of tested patients.
Conclusion: The clinical basis for the diagnostics of PID was largely in accordance with the criteria
in the CDC 2002 Guidelines. The limited number of CT tests performed is somewhat
disappointing, considering the fact that effective disease prevention includes widespread CT
screening. Further studies in different settings are needed in order to analyze how the testing rate
for CT can be improved in clinical praxis.
Background
Pelvic inflammatory disease (PID) includes endometritis,
salpingitis, tubo-ovarian abscess, and/or pelvic peritonitis
[1]. PID is a relatively common disease; in the U.S. around
8% of all women will have PID during their reproductive
period [2], and in the U.K. PID contributes to about 2% of
the yearly visits in general practice [3,4]. Causative agents
are the sexually transmitted infections C. Trachomatis and
N. Gonorrhoeae but may include several other bacteria,
such as anaerobic Gram-negative rods and Mycoplasma
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Genitalium [5,6]. The complications of PID include infer-
tility and ectopic pregnancy, which in turn causes substan-
tial medical and social consequences for the affected
individuals.
In addition, the financial burden on society for infertility
examinations and treatments is considerable [7]. Diagno-
sis of PID is difficult because symptoms among women
with PID vary widely from severe to none. For example, as
many as 50% of women with tubal disease at infertility
examination or ectopic pregnancy report having had no
PID [8]. Moreover, some of these women have visited
doctors for lower abdominal symptoms, not recognized
as PID [9].
National Guidelines for PID from the US Center of Dis-
ease Control and Prevention (CDC 2002 Guidelines)
gradually modified the criteria for clinical diagnosis in
1998 and 2002 in order to cover milder forms of PID
[1,10]. The aim was to minimize missed diagnoses and
reduce serious complications of PID. Clinicians are rec-
ommended to apply a low threshold for treatment of sus-
pected cases. The current criteria proposed by CDC 2002
Guidelines imply maximal sensitivity, while partly sacri-
ficing specificity. However, the low threshold for treat-
ment of suspected cases should be maintained due to the
severe complications of undetected PID, and because
mild, atypical and silent cases of PID are common,
expressed in the U.K. Prodigy guidance on PID as "Many
women have no symptoms" [4].
The clinical diagnosis of acute PID is imprecise and has a
positive predictive value for salpingitis of 65% to 90%
compared with laparoscopy [1]. However, for most
patients with PID, laparoscopic examination will not be
applicable for practical and economic reasons. Therefore,
the PID diagnosis will in the large majority of cases be
based on clinical findings.
The aim of this retrospective study was to describe the
clinical basis for the diagnostics of PID in a Swedish hos-
pital setting and compare them with the diagnostic crite-
ria of the CDC 2002 Guidelines. For this purpose we
determined the frequency of reported symptoms and
signs, and performed examinations among all out-
patients who were clinically diagnosed with PID at the
obstetric and gynecological emergency department
(OGED) in a Swedish university hospital during 2001.
Methods
All 189 out-patients with clinical PID were diagnosed in
OGED at the Karolinska University Hospital, site Hud-
dinge, which gives service to 350,000 inhabitants in
southern Stockholm. Referral by another doctor is not
needed. Almost all Swedish health care is financed by the
taxpayers and the patient fee is low. Thus, the OGED
receives a very high proportion of women with lower
abdominal pain, bleedings, abnormal discharge, and
acute genital infections.
The medical history data were collected by the gynecolo-
gist on duty. No uniform data collection form was used. A
pelvic examination, i.e. a bimanual vaginal palpation, was
performed in all cases followed by, in 82% of the cases, a
transvaginal sonography (TVS). The time available was
approximately 20–25 minutes.
There were 4,671 gynecological patients treated at the
OGED in 2001 and we checked all their ICD-10 codes
(International Classification of Diseases, tenth revision)
in the electronic medical records (EMR). There were 381
patients with ICD-10 codes for PID (N70.0–N71.9;
N73.0–N73.5). Women with an obvious cause of their
PID were excluded, i.e. women with PID following partus,
miscarriage, abortion, insertion of IUD and intra-uterine
operations (n = 175). Sixteen in-patients were also
excluded. The inclusion criteria gave 189 out-patients
with PID diagnosis for the study.
We extracted from all 189 patient's EMR background data
(age, parity, contraceptive method) length of history,
symptoms and signs, pelvic examination, laboratory tests
and medication. The length of history was determined by
the symptom with the longest reported duration.
For each laboratory test, there were tested and non-tested
patients. C-reactive protein (CRP) was analyzed via a cap-
illary test. A urine specimen was requested from all
patients before the pelvic examination and 52% were able
to produce it (n = 98). The urine was analyzed for leuco-
cyturia, measured by a test stick.
Urine culture was performed in 28 patients, probably
when there was a suspicion of a combination of PID and
UTI.
C. Trachomatis (CT) was analyzed with a polymerase
chain reaction (PCR) method (Roche COBOS Amplicor®).
A swab was taken always from the endocervix and mostly
from the urethra. N. Gonorrhoeae (NG) was cultured via
an endocervical swab.
Ethics
This study was approved by the Ethics Committee at Karo-
linska Institutet, Stockholm, in 1999/2000.
Results
More than half of the 189 patients were 30 years old or
younger and 36% were childless. Twenty-four percent had
an IUD. More than 50% of the patients had a length ofBMC Women's Health 2006, 6:16 http://www.biomedcentral.com/1472-6874/6/16
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history up to one week, and around 20% more than one
month (Table 1). Thirty-nine patients had visited a doc-
tor, mostly a GP, within days or weeks before they came
to the OGED. Fifteen of those had been treated for sus-
pected UTI and another 15 patients had visited a gynecol-
ogist, without receiving PID treatment (data not shown).
Abdominal pain was reported by 98%, abnormal vaginal
discharge by 45%, while feelings of sickness, dysuria, fever
and/or chills, lower back pain, and abnormal bleedings
were each reported by 24–30% of the patients. Pain at
intercourse was reported by 5%. All 189 patients were ten-
der at examination. Almost half of the patients had ten-
derness over the uterus and/or motion tenderness of
cervix and both adnexa, 20% were tender over the uterus
and/or cervix only, 19% over the uterus and one of the
adnexa and 12% over the adnexa only (Table 2).
CT was detected among 5% of the 98 tested patients,
while no NG was detected among the 23 tested patients.
The CRP was normal (< 10) among more than 50% of the
110 tested patients. About 50% of the 98 patients who
were able to produce a urine test had leucocyturia.
Urine culture was positive (> 100,000 bacteria per ml)
among 6 of the 28 tested patients with suspicion of having
both PID and UTI. TVS was performed in 156 patients.
Ovarial cysts were found in 15% of them and in 5% there
was pelvic fluid (Table 3).
Wet smear was performed among less than 20% of the
patients. All 189 patients were given oral treatment with
Table 3: Results of the laboratory tests and the transvaginal 
sonography among the tested subgroups of the 189 patients 
diagnosed with PID.
percentage
C-reactive protein n = 110/189
< 10 (normal) 55
≥10(elevated) 45
Urine leucocytes n = 98/189
Negative 54
Positive 46
C. Trachomatis n = 98/189
Positive 5
N. Gonorrhoeae n = 23/189
Positive 0
Transvaginal sonography n = 156/189
Ovarial cysts
no cysts 85
cyst < 10 mm 3
cyst < 20 mm 8
cyst < 21–40 mm 3
cyst > 41 mm 1
Fluid
Yes 5
No 95
Table 1: Age, parity, contraceptive method, and length of history 
(in percentages) among the 189 patients with diagnosed PID.
Percentage
Age (years)
15–20 13
21–30 40
31–40 29
> 40 18
Parity
0-para 36
1-para 15
2-3-para 36
≥4-para 4
Unknown 9
Contraceptive method
IUD 24
Oral contraception 18
Sterilization or long-acting progesterone 8
No specified method 50
Length of history
1–7 days 52
1–2 weeks 6
2–4 weeks 24
1–3 months 15
3–6 months 4
> 6 months 2
Table 2: Frequency (percentages) of the symptoms and signs and 
tenderness at examination among the 189 patients diagnosed 
with PID.
percentage
Symptoms 
Abdominal pain 98
Abnormal vaginal discharge 45
Feelings of sickness 30
Dysuria 27
Fever and/or chills 25
Lower back pain 25
Abnormal bleedings 24
Pain at intercourse 5
Tenderness at examination
Uterus and/or motion of cervix and both adnexa 49
Uterus and/or motion of cervix only 20
Uterus and/or motion of cervix and one adnexa 19
Both adnexa (uterus untender) 6
One adnexa (uterus untender) 6BMC Women's Health 2006, 6:16 http://www.biomedcentral.com/1472-6874/6/16
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antibiotics; 55% received doxycycline and metronidazol,
23% received cefuroxim or cefalexin and metronidazol,
and 22% were given other antibiotic treatment (data not
shown).
Discussion
The main finding of this study was that the clinical basis
for the diagnostics of PID was largely in accordance with
the symptoms and signs mentioned in the CDC Guide-
lines. For example, clinical symptoms mentioned in the
CDC 2002 Guidelines as criteria for diagnosis are abdom-
inal pain, abnormal vaginal discharge and fever, while
abnormal bleedings and pain at intercourse are men-
tioned as possible, albeit non-specific PID symptoms.
The above-mentioned symptoms from the CDC 2002
Guidelines were all reported among the patients in our
study. The most frequent symptom was abdominal pain,
followed by abnormal vaginal discharge. Other common
symptoms were fever and/or chills and abnormal bleed-
ings, whereas pain at intercourse was a rarer symptom. In
addition, feelings of sickness, dysuria, and lower back
pain were all frequent symptoms among our patients,
although not mentioned in the CDC 2002 Guidelines.
CDC 2002 Guidelines recommend antibiotic treatment of
suspected PID if (1) cervical motion tenderness or (2)
uterine or adnexal tenderness is present and no other
cause is identified. The doctors in this study performed a
bimanual examination on all 189 patients, and found
that all had cervical motion tenderness or were tender
over the uterus and/or the adnexa. In addition, 19% of the
patients were tender over the uterus and the adnexa, and
20% had only uterine tenderness, which is in agreement
with the CDC 2002 Guidelines and with some previous
studies [11,12].
CDC 2002 Guidelines do not mention the degree of ten-
derness, which is understandable considering its subjec-
tive dimension. However, most of the doctors that
examined the patients in this study used three degrees of
assessed tenderness in the bimanual examination; light,
moderate and pronounced. A few previous PID studies
have used a severity score of tenderness with three degrees
in treatment evaluations, including the recent large-scale
PEACH study [13-15].
Additional diagnostic criteria in the CDC guidelines
include the presence of white blood cells on wet smear,
elevated erythrocyte sedimentation rate, elevated C-reac-
tive protein, a positive culture of CT or NG and a TVS that
shows fluid-filled thickened tubes, with or without pelvic
fluid.
In our study wet smear was performed among less than
20% of the patients. Erythrocyte sedimentation rate was
not used in the diagnostic procedure, possibly because it
has largely been replaced by C-reactive protein in acute
medical consultations in Sweden. Most of the 110 tested
patients had normal or low CRP. In the CDC 2002 Guide-
lines an elevated CRP is an additional criterion supporting
a PID diagnosis, while a normal CRP cannot exclude it
[16].
About half of the patients were tested for CT, giving a prev-
alence rate among the tested patients of 5%. The low test-
ing rate for CT observed in the present study is somewhat
disappointing considering the fact that summarized stud-
ies of the cost effectiveness of screening for CT have shown
that it is cost-saving to overtest symptomatic women at a
prevalence as low as 1.1% [17]. In addition, a study from
1996 found evidence that screening for CT had reduced
PID in women by as much as 60% [18]. The low testing
rate for CT in the present study could have resulted in
inadequate treatment of partners and the subsequent rein-
fection of some women after antibiotic treatment.
However, the relatively low detected rate of CT (5%)
among the tested patients is in accordance with other
Swedish studies of the prevalence of CT. In a Swedish lon-
gitudinal study, CT rates in PID patients in a hospital set-
ting decreased from 17% in 1988 to < 5% in 1997 [19,20].
It has been mandatory by law since 1988 to report posi-
tive CT cases to the Stockholm Regional Department of
Communicable Diseases, Control and Prevention [21].
However, despite (or perhaps even because of) mandatory
notification of CT cases, doctors did not test a sufficient
proportion of the PID patients for CT.
The low testing rate for NG follows Swedish traditions, i.e.
testing mainly patients with pronounced risk behavior, at
the patient's own request, when tracing contacts and after
therapy failure in patients with PID and urethritis. In a
Swedish study, the rates of NG in PID patients treated in
hospital care was 0% in both 1988 and 1997 [19,20].
In contrast, a study from the U.K. found that the rates of
gonococcal PID were increasing [22]. A systematic review
from the UK found that healthcare settings had higher CT
rates than population-based studies, where the overall
prevalence was 5% [23]. However, in some settings in the
U.S. and in the UK, the STI rates are considerably higher.
Studies of PID patients have shown that the CT and NG
rates are 15–30% and 10–20%, respectively; however, this
is mainly in inner-city settings [15,22]. In Antwerp, Bel-
gium, the overall prevalence of CT among sexually active
women was 5% [24], which is in accordance with the
present study.BMC Women's Health 2006, 6:16 http://www.biomedcentral.com/1472-6874/6/16
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The prevalence of CT varies with age, i.e. younger women
have a higher prevalence rate of CT than older women
[23]. We examined possible differences between women
that were tested for CT and women that were non-tested.
Tested women had a mean age of 27 years and non-tested
of 35. Older women were possibly considered less impor-
tant to test.
TVS was performed among a large proportion of our
patients, possibly to exclude differential diagnoses. It is
possible that TVS was overused, because TVS cannot rule
out mild to moderate PID, and none of our patients had
TVS-specific signs [25] at the TVS examination. A study
from Finland found that Power Doppler TVS was 100%
sensitive and 80% specific in the diagnosis of PID, i.e. the
overall accuracy was 93% [25]. Other studies have con-
firmed the usefulness of TVS in the diagnosis of PID [26-
29]. However, usefulness is probably highly related to
each doctor's experience with using TVS in the diagnosis
of PID.
Dysuria is not mentioned as a diagnostic criterion of PID
in the CDC 2002 Guidelines. However, it is mentioned as
a PID criteria in the CDC Pelvic Inflammatory Disease –
CDC Fact Sheet for the public 2004 [30]. In some of our
patients dysuria may have been caused by e.g. undiag-
nosed UTI or the PID itself.
Time aspects are not discussed in the CDC 2002 Guide-
lines. In this study, the majority had a short symptom his-
tory, which is in agreement with the PEACH study [15].
However, as many as 20% had a symptom history of more
than one month and 21% had visited a doctor shortly
before they came to the OGED, which suggests that some
of these patients might, at least initially, have presented
mild or atypical symptoms of PID.
The key strength of this study was that the retrospective
design meant that the doctors' management of the
patients was unbiased by, for example, any intervention.
In addition, the sample size and the inclusion of relatively
non-selected open-care patients could be seen as addi-
tional strengths of this study.
As inherent in all studies of clinically diagnosed PID,
some of the patients in this study did not have PID. Addi-
tionally, our data did not allow us to include missed cases
of PID, as the extracted electronic medical records of the
189 patients only included diagnosed cases of PID that
were based on the ICD codes. However, the aim of this
study was to describe the clinical basis for diagnosis and
treatment among the 189 patients, and not to determine
how many of them actually had PID. It is possible that the
emergency ward environment may have affected the qual-
ity of the case notes, and that not all information that the
doctors used for their management of the patients was
included in the records.
The authors of a retrospective chart review set out to deter-
mine whether emergency department practitioners at an
urban teaching hospital in the US complied with CDC
guidelines for diagnosing and treating sexually transmit-
ted diseases. They found a number of deficits in the adher-
ence to recommended guidelines [31]. A national study
from England and Wales assessed the quality of the diag-
nosis and treatment of PID in general practice. The find-
ings of that study reflected a low disease awareness and
sub-optimal management of PID, which the authors con-
cluded was a fundamental obstacle to effective disease
intervention [32].
Conclusion
The clinical basis for the diagnostics of PID was largely in
accordance with the criteria in the CDC 2002 Guidelines.
The limited number of CT tests performed (52%) is some-
what disappointing considering the fact that effective dis-
ease prevention includes widespread screening. In
addition, some of our patients had a relatively long symp-
tom history, which suggests that they might initially have
presented mild or atypical symptoms of PID. Further stud-
ies could therefore focus on symptoms and signs in milder
forms of PID, and how the testing rate for CT can be
improved in clinical praxis.
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